SaphnerT., TormeyD.C., GrayR.Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol.1996; 14: 2738–2746.
2.
GelmannE.P.Tamoxifen induction of apoptosis in estrogen receptor-negative cancers: new tricks for an old dog?J Natl Cancer Inst.1996; 88: 224–226.
3.
KangY., CortinaR., PerryR.R.Role of c-myc in tamoxifen-induced apoptosis in estrogen-independent breast cancer cells. J Natl Cancer Inst.1996; 88: 279–284.
4.
Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet.1992; 339: 1–15, 71–85.
5.
Swedish Breast Cancer Cooperative Group.Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst.1996; 88: 1543–1549.
6.
Current Trials Working Party of the Cancer Research Campaign Breast Cancer Trials Group. Preliminary results from the Cancer Research Campaign Trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. J Natl Cancer Inst.1996; 88: 1834–1839.
7.
FisherB., DignamJ., BryantJ.Five years versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst.1996; 88: 1529–1542.
8.
StewartH.J., ForrestA.P., EveringtonD.Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. Br J Cancer.1996; 74: 297–299.
9.
PowlesT.J.Efficacy of tamoxifen as treatment of breast cancer. Semin Oncol.1997; 21(suppl 1): S1–S48 S154.
10.
TormeyD.C., GrayR., FalksonH.C.Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph-node-positive breast cancer. J Natl Cancer Inst.1996; 88: 1828–1833.
11.
PetoR.Five years of tamoxifen - or more?J Natl Cancer Inst.1996; 88: 1791–1793.
12.
HudisC.A., NortonL.Adjuvant drug therapy for operable breast cancer. Semin Oncol.1996; 23: 475–493.
13.
NSABP halts B-14 trial: no benefit seen beyond 5 years of tamoxifen use. J Natl Cancer Inst.1995; 87: 1829.
14.
GottardisM.M., MartinM.K., JordanV.C.Long-term tamoxifen therapy to control transplanted human breast tumor growth in athymic mice. In: SalmonS.E., ed. Adjuvant Therapy of Cancer.5th ed.Orlando, Fla: Grune & Stratton, Inc; 1987: 447–453.
15.
JordanV.S.A therapy withdrawal can make a strategic advance. Ann Oncol.1992; 3: 587–588.
16.
MorrowM., JordanV.S.Molecular mechanisms of resistance to tamoxifen therapy in breast cancer. Arch Surg.1993; 128: 1187–1191.
17.
BilimoriaM.M., AssikisV.J., JordanJ.C.Should adjuvant tamoxifen therapy be stopped at 5 years?Cancer J Sci Am.1996; 2: 140–150.
18.
HowellA., DeFriendD.J., RobertsonJ.F.R.Pharmacokinetics, pharmacological and anti-tumor effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. Br J Cancer.1996; 74: 300–308.
